AP-2α gene deregulation is associated with renal cell carcinoma patient survival.

ABSTRACT:

Background

Renal cell carcinoma (RCC), one of the most fatal urologic tumors, accounts for approximately 3% of all adult cancers and exhibits a high metastatic index at diagnosis and a high rate of relapse. Radical or partial nephrectomy is a curative option for nonmetastatic RCCs. Targeted therapy has been shown to improve the survival of patients with metastatic RCCs. However, the underlying cellular and molecular events associated with RCC pathogenesis are not well known.

Methods

To investigate the clinical role of the transcription factor activator protein (AP)-2α in RCC, methylated CpG island recovery assays and microarray analysis were employed. COBRA and RT‒qPCR assays were performed to assess AP-2α expression in RCC.

Results

A negative correlation was noted be

SUBMITTER: Lin PH 

PROVIDER: S-EPMC11304775 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature